轻型卒中前残疾的大血管闭塞性卒中血管内治疗的成本效益:HERMES协作组结果
基于HERMES协作组7项随机EVT试验的患者水平数据,构建短期决策模型与长期马尔可夫模型,评估卒中前mRS 1-2分的大血管闭塞患者中EVT联合最佳药物治疗的成本效益。结果显示EVT联合治疗终身节省2821美元(医疗视角)或5378美元(社会视角),增加1.27个质量调整生命年,具有经济学优势。
要点
- 卒中前mRS 1-2分的大血管闭塞患者,EVT联合最佳药物治疗相比单纯药物治疗节省终身成本并增加QALY。
- 医疗视角节省2821美元,社会视角节省5378美元,增量QALY为1.27。
- 在10万美元/QALY和5万美元/QALY的支付意愿阈值下,EVT联合治疗的净货币收益均更高。
核心结论
- 从卫生经济学角度,对于急性缺血性卒中大血管闭塞且卒中前症状/残疾轻微的患者,EVT联合最佳药物治疗应为首选策略。
研究设计与样本
- 数据来自HERMES协作组,该协作组汇总了7项大型随机EVT试验的患者水平数据。
- 采用决策模型,包括分析索引卒中后90天内成本和功能结局的短期模型,以及估计终身成本和结局的长期马尔可夫状态转换模型(周期长度12个月),从医疗和社会视角进行分析。
- 计算增量成本效益比和净货币收益,并进行概率敏感性分析。
主要发现
- EVT联合最佳药物治疗相比单纯最佳药物治疗,终身节省成本2821美元(医疗视角)或5378美元(社会视角),并增加1.27个质量调整生命年,表明额外EVT作为治疗策略具有优势。
- 在较高(100 000美元/QALY)和较低(50 000美元/QALY)支付意愿阈值下,EVT联合最佳药物治疗的净货币收益均高于单纯最佳药物治疗。
- 概率敏感性分析显示,与单纯最佳药物治疗相比,额外EVT成本降低且质量调整生命年增加。
关键数值与推荐
- 卒中前症状/残疾轻微定义为改良Rankin量表评分为1或2分。
- 增量成本效益比和净货币收益的计算基于医疗和社会视角。
- 支付意愿阈值分别为100 000美元/QALY和50 000美元/QALY。
临床怎么用
- 从卫生经济学角度,对于急性缺血性卒中大血管闭塞且卒中前症状/残疾轻微的患者,EVT联合最佳药物治疗应为首选策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical and economic benefit of endovascular treatment (EVT) in addition to best medical management in patients with stroke with mild preexisting symptoms/disability is not well studied. We aimed to investigate cost-effectiveness of EVT in patients with large vessel occlusion and mild prestroke symptoms/disability, defined as a modified Rankin Scale score of 1 or 2. METHODS: Data are from the HERMES collaboration (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials), which pooled patient-level data from 7 large, randomized EVT trials. We used a decision model consisting of a short-run model to analyze costs and functional outcomes within 90 days after the index stroke and a long-run Markov state transition model (cycle length of 12 months) to estimate expected lifetime costs and outcomes from a health care and a societal perspective. Incremental cost-effectiveness ratio and net monetary benefits were calculated, and a probabilistic sensitivity analysis was performed. RESULTS: EVT in addition to best medical management resulted in lifetime cost savings of $2821 (health care perspective) or $5378 (societal perspective) and an increment of 1.27 quality-adjusted life years compared with best medical management alone, indicating dominance of additional EVT as a treatment strategy. The net monetary benefits were higher for EVT in addition to best medical management compared with best medical management alone both at the higher (100 000$/quality-adjusted life years) and lower (50 000$/quality-adjusted life years) willingness to pay thresholds. Probabilistic sensitivity analysis showed decreased costs and an increase in quality-adjusted life years for additional EVT compared with best medical management only. CONCLUSIONS: From a health-economic standpoint, EVT in addition to best medical management should be the preferred strategy in patients with acute ischemic stroke with large vessel occlusion and mild prestroke symptoms/disability.
引用
- Ospel JM, Kunz WG, McDonough RV, et al. Cost-Effectiveness of Endovascular Treatment in Large Vessel Occlusion Stroke With Mild Prestroke Disability: Results From the HERMES Collaboration. Stroke. 2022. PMID: 36472199. doi:10.1161/STROKEAHA.121.038407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。